Impact ledger
Scholar Rock Holding Corporation (SRRK): the developments shaping its investment case
Follow the evidence affecting Scholar Rock Holding Corporation's valuation assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-08-06 | multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. |
| 2026-08-06 | share_count | Bullish | Primary equity issuance increases diluted share count. |
Event impact log
8 events mapped to SRRK since 2026-09-12. Evidence through 2026-09-14.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | Direct commercialization of a novel therapeutic, market entry into a high-value rare disease segment. | Bullish | 1-3m | 0.90 |
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | Direct product approval and commercialization opportunity. This is a significant milestone for a biotech company, transitioning from R&D to revenue generation. | Bullish | 1-3m | 0.90 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA Therapy | Direct regulatory approval for lead product, enabling market entry and revenue generation. | Bullish | 1-3m | 0.90 |
| 2026-09-13 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | Direct revenue generation from drug sales, transition to commercial-stage biopharma. | Bullish | 1-3m | 0.90 |
| 2026-09-12 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | Direct market entry and revenue generation for lead product. | Bullish | 1-3m | 0.90 |
| 2026-09-12 | FDA Approves Isembyld for Spinal Muscular Atrophy | Direct revenue generation from drug sales, increased market valuation due to successful R&D, potential for future pipeline validation. | Bullish | 1-3m | 0.90 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy | Direct product approval leading to market entry and revenue generation. | Bullish | 1-5y | 0.90 |
| 2026-09-12 | FDA approves Scholar Rock's Isembyld for spinal muscular atrophy | Direct regulatory approval leading to commercialization, shifting from R&D to sales-driven operations. | Bullish | 1-3m | 0.90 |
Continue this research
Build your Scholar Rock Holding Corporation investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the SRRK entity page →